JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment

Annals of the Rheumatic Diseases

Volumn 76, Issue 8, 2017, Pages 1467-1475

  Zhang, Yun ^a   Liang, Ruifang ^a   Chen, Chih Wei ^a   Mallano, Tatjana ^a   Dees, Clara ^a   Distler, Alfiya ^a   Reich, Adam ^b   Bergmann, Christina ^a   Ramming, Andreas ^a   Gelse, Kolja ^c   Mielenz, Dirk ^d   Distler, Oliver ^e   Schett, Georg ^a   Distler, Jörg H W ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

fibroblasts; HSP90; JAK; TGF ; transactivation

Indexed keywords

ALVESPIMYCIN; JANUS KINASE 1; JANUS KINASE 2; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; RUXOLITINIB; 17-(DIMETHYLAMINOETHYLAMINO)-17-DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC ANTIBIOTIC; BENZOQUINONE DERIVATIVE; BLEOMYCIN; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME INACTIVATION; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; LONG TERM CARE; LUNG FIBROSIS; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN FIBROSIS; TRANSPHOSPHORYLATION; ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; IMMUNOHISTOCHEMISTRY; LUNG; METABOLISM; MIDDLE AGED; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SYSTEMIC SCLEROSIS; WESTERN BLOTTING;

ADULT; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; BLEOMYCIN; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; FIBROBLASTS; FIBROSIS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; JANUS KINASE 1; JANUS KINASE 2; LACTAMS, MACROCYCLIC; LUNG; MALE; MICE; MIDDLE AGED; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PULMONARY FIBROSIS; PYRAZOLES; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; SCLERODERMA, SYSTEMIC; SULFONAMIDES; TRANSFORMING GROWTH FACTOR BETA;

EID: 85024402192     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210911     Document Type: Article

References (34)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
2. T yndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809-15.
3. Ramming A, Dees C, Distler JH. From pathogenesis to therapy-perspective on treatment strategies in fibrotic diseases. Pharmacol Res 2015;100:93-100.
4. Samarakoon R, Overstreet JM, Higgins PJ. TGF-signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities. Cell Signal 2013;25:264-8.
5. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. Faseb J 2004;18:816-27.
6. Sonnylal S, Denton CP, Zheng B, et al. Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 2007;56:334-44.
7. Distler JH, Feghali-Bostwick C, Soare A, et al. Frontiers of antifibrotic therapy in systemic sclerosis. Arthritis & rheumatology 2016.
8. D ees C, Tomcik M, Palumbo-Zerr K, et al. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor in systemic sclerosis. Arthritis Rheum 2012;64:3006-15.
9. P ardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007;21:1658-68.
10. Tomcik M, Zerr P, Pitkowski J, et al. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-signalling to prevent fibrosis. Ann Rheum Dis 2014;73:1215-22.
11. Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 2014;123:3832-42.
12. Koppikar P, Bhagwat N, Kilpivaara O, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012;489:155-9.
13. Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 2013;122:1192-202.
14. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115:3109-17.
15. D istler A, Deloch L, Huang J, et al. Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical wnt signalling. Ann Rheum Dis 2013;72:1575-80.
16. Zhang Y, Dees C, Beyer C, et al. Inhibition of casein kinase II reduces TGFinduced fibroblast activation and ameliorates experimental fibrosis. Ann Rheum Dis 2015;74:936-43.
17. P alumbo K, Zerr P, Tomcik M, et al. The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis 2011;70:1320-6.
18. Mallano T, Palumbo-Zerr K, Zerr P, et al. Activating transcription factor 3 regulates canonical TGF signalling in systemic sclerosis. Ann Rheum Dis 2016;75:586-92.
19. D ees C, Schlottmann I, Funke R, et al. The wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann Rheum Dis 2014;73:1232-9.
20. D ees C, Tomcik M, Zerr P, et al. Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis 2011;70:1304-10.
21. Kim BH, Jee JG, Yin CH, et al. NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3. Mol Cancer 2010;9:36.
22. Hattori N, Degen JL, Sisson TH, et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J Clin Invest 2000;106:1341-50.
23. Liang R, Šumová B, Cordazzo C, et al. The transcription factor GLI2 as a downstream mediator of transforming growth factor-induced fibroblast activation in SSc. Ann Rheum Dis 2016;76:756-64.
24. Khodzhigorova A, Distler A, Lang V, et al. Inhibition of sumoylation prevents experimental fibrosis. Ann Rheum Dis 2012;71:1904-8.
25. Akhmetshina A, Palumbo K, Dees C, et al. Activation of canonical wnt signalling is required for TGF-mediated fibrosis. Nat Commun 2012;3:735.
26. Beyer C, Reich N, Schindler SC, et al. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann Rheum Dis 2012;71:1019-26.
27. Beyer C, Reichert H, Akan H, et al. Blockade of canonical wnt signalling ameliorates experimental dermal fibrosis. Ann Rheum Dis 2013;72:1255-8.
28. Huang J, Beyer C, Palumbo-Zerr K, et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis 2016;75:883-90.
29. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988;41:467-70.
30. Höbner R-H, Gitter W, Eddine El Mokhtari N, et al. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques 2008;44:507-17.
31. Marubayashi S, Koppikar P, Taldone T, et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest 2010;120:3578-93.
32. Sunaga H, Matsui H, Ueno M, et al. Deranged fatty acid composition causes pulmonary fibrosis in Elovl6-deficient mice. Nat Commun 2013;4:2563.
33. Faress JA, Nethery DE, Kern EF, et al. Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2. J Appl Physiol 2007;103:2077-83.
34. R adovanac K, Morgner J, Schulz JN, et al. Stabilization of integrin-linked kinase by the Hsp90-CHIP axis impacts cellular force generation, migration and the fibrotic response. Embo J 2013;32:1409-24.